Comparative Study
doi: 10.1038/nm1456.
Epub 2006 Jul 23.
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines
Affiliations
- PMID: 16862151
- DOI: 10.1038/nm1456
Item in Clipboard
Comparative Study
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines
Nat Med.
2006 Aug.
Free article
Abstract
Heat, oxidation and exposure to aldehydes create reactive carbonyl groups on proteins, targeting antigens to scavenger receptors. Formaldehyde is widely used in making vaccines, but has been associated with atypical enhanced disease during subsequent infection with paramyxoviruses. We show that carbonyl groups on formaldehyde-treated vaccine antigens boost T helper type 2 (T(H)2) responses and enhance respiratory syncytial virus (RSV) disease in mice, an effect partially reversible by chemical reduction of carbonyl groups.
Similar articles
-
Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.Vaccine. 2007 Jul 20;25(29):5378-89. doi: 10.1016/j.vaccine.2007.05.004. Epub 2007 May 24. Vaccine. 2007. PMID: 17561317
-
Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.Eur J Immunol. 2014 Aug;44(8):2349-59. doi: 10.1002/eji.201344206. Epub 2014 Jun 5. Eur J Immunol. 2014. PMID: 24796717
-
Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.Clin Diagn Lab Immunol. 2005 Jan;12(1):171-9. doi: 10.1128/CDLI.12.1.171-179.2005. Clin Diagn Lab Immunol. 2005. PMID: 15643003 Free PMC article.
-
Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.Expert Rev Vaccines. 2004 Dec;3(6):693-700. doi: 10.1586/14760584.3.6.693. Expert Rev Vaccines. 2004. PMID: 15606354 Review.
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
Cited by
-
Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model.Viruses. 2023 Aug 30;15(9):1846. doi: 10.3390/v15091846. Viruses. 2023. PMID: 37766253 Free PMC article.
-
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.NPJ Vaccines. 2023 Jul 13;8(1):101. doi: 10.1038/s41541-023-00696-w. NPJ Vaccines. 2023. PMID: 37443366 Free PMC article.
-
Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein.Microbiol Spectr. 2023 Aug 17;11(4):e0135823. doi: 10.1128/spectrum.01358-23. Epub 2023 Jun 5. Microbiol Spectr. 2023. PMID: 37272801 Free PMC article.
-
A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years of Age.Vaccines (Basel). 2023 May 18;11(5):999. doi: 10.3390/vaccines11050999. Vaccines (Basel). 2023. PMID: 37243103 Free PMC article.
-
SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo.Microorganisms. 2023 Apr 13;11(4):1015. doi: 10.3390/microorganisms11041015. Microorganisms. 2023. PMID: 37110438 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
